Cytomegalovirus Cell-Mediated Immunity

Completed

Conditions studied: Cytomegalovirus Infections

In brief

Cytomegalovirus (CMV) is an important cause of illness and occasional deaths in infants who catch the virus before they are born, in newborns, and in children and adults who have weak immune systems. The purpose of this study is to look at how the CMV vaccine works in the blood. This study is being done along with the main CMV gB/MF59 vaccine study that looks at how the overall body reacts to the vaccine. Participants will include up to 100 healthy adolescent female subjects aged 12 to 17 years who were vaccinated in study 04-039 and 100 subjects that were screened for 04-039 to participate as controls. Study procedures will include up to 6 blood draws taken over a 13 month period. Participation will be about 31 months (unless the patient enrolls into the shedding study).

Key facts

Study ID
NCT00815165
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
People needed
165
Starts
2006-06-01
Expected to finish
2011-08-01
Last updated by the study team
2013-09-09

Who can join

Age: 12 and older, up to 17. Sex: female. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.